Compare · NVRO vs RMD
NVRO vs RMD
Side-by-side comparison of Nevro Corp. (NVRO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVRO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 15.8x NVRO ($2.15B).
- RMD has hit the wire 9 times in the past 4 weeks while NVRO has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Nevro Corp.
- ResMed Inc.
- Price
- $5.84+0.00%
- $239.08-1.35%
- Market cap
- $2.15B
- $34.07B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 9
- Recent ratings
- 25
- 25
Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NVRO
- SEC Form 15-12G filed by Nevro Corp.
- SEC Form EFFECT filed by Nevro Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.
- Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Financial Officer Macleod Roderick H. returned 350,663 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demane Michael F returned 503,618 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Karros Kirt P returned 17,452 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oboyle Kevin C returned 43,396 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target